Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1101 vs bevacizumab plus paclitaxel/carboplatin in non-squamous NSCLC
CTR20161024Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of QL1101 in Non-small cell lung cancer (NS-NSCLC), sponsored by Qilu Pharmaceutical. Started Dec 2016; status: completed.
02
Drugs
QL1101
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20161024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20161024.